Hypothalamic Diseases  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
PAOLA, NCT01137682 / 2009-016722-13: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Completed
3
198
US, Canada, Europe, RoW
Pasireotide, SOM230, octreotide LAR 30mg, lanreotide ATG 120mg
Novartis Pharmaceuticals
Acromegaly
01/13
02/17
NCT00600886 / 2007-001972-36: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Completed
3
358
US, Canada, Europe, RoW
Pasireotide, SOM230, Octreotide
Novartis Pharmaceuticals
Acromegaly
03/16
03/16
NCT01374906 / 2009-011128-70: Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Completed
3
150
Japan, US, Canada, Europe, RoW
pasireotide LAR, SOM230, SOM230 LAR 30 mg, SOM230 LAR 10 mg
Novartis Pharmaceuticals
Cushing's Disease
12/16
12/16

Download Options